CA
NZ
UK
AU
IND
US
The scale of this strategic pivot is reflected clearly in the transaction's ownership structure: existing Matinas stockholders will retain only roughly 9% ownership in the reorganized company. A retained stake this modest signals that the substantial majority of the combined company's future equity value …
NanoKnife is a irreversible electroporation-based tissue ablation platform, a technology that uses electrical pulses to destroy targeted tissue without relying on heat or cold-based ablation methods, offering a differentiated approach for treating tumors in anatomically sensitive locations where thermal ablation techniques may pose greater …
For the full fiscal year, pro forma net sales climbed 9.4% to $320.2 million, a growth rate driven predominantly by an 18.4% surge in Med Tech revenue to $150.0 million. This strong Med Tech performance more than offset a comparatively modest 2.5% increase in …
The defining feature of AVR-001 is its engineered pharmacokinetic profile: the molecule has been designed with an approximately 100-hour half-life, enabling once-weekly oral administration. This is a notable achievement in peptide drug design, as cyclic peptides have historically faced challenges achieving the metabolic stability …
Overall survival is widely considered the gold-standard endpoint in oncology clinical trials, since it directly measures whether a treatment helps patients live longer rather than relying on surrogate markers. A survival result of 30.9 months is notable on its own, but becomes even more …
Dravet syndrome is a rare and severe form of epilepsy that typically begins in infancy, characterized by frequent, prolonged seizures and significant developmental impact. ION337 represents Ionis's antisense oligonucleotide approach to addressing the underlying genetic drivers of this difficult-to-treat condition, and the initiation of …
The new data, drawn from post-hoc exploratory analysis of the company's Phase 2a CLEAR MIND study, demonstrated that laromestrocel (also known as lomecel-B), a mesenchymal stem cell therapy, reduced free water neuroinflammation and neural degradation markers in treated Alzheimer's patients. These imaging-based biomarkers of …
Central to today's selloff is the dilution embedded in the transaction structure: under the terms of the merger, existing Matinas shareholders will retain only approximately 9% equity in the combined entity. A retained ownership stake this small for legacy shareholders is a significant factor …
The topline results showed a 35.3% mean reduction in Severity of Alopecia Tool (SALT) scores within the modified intent-to-treat population, alongside a 40% SALT-20 response rate — meaning a substantial share of treated patients achieved hair regrowth covering at least 80% of the scalp, …
Borie's appointment as CMO and Head of R&D positions the company with dedicated immunology leadership ahead of a string of important near-term clinical milestones. Chief Medical Officer hires of this kind are typically evaluated by investors based on the incoming executive's track record and …
Please wait processing your request...